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Letters
RESEARCH LETTER
Change in Distance to Nearest Facility and Abortion
in Texas, 2012 to 2014
Texas House Bill 2, enacted in 2013, was one of the most
restrictive abortion laws in the country before the US
Supreme Court ruled in June 2016 that 2 provisions were
unconstitutional.
Following introduction and passage of the bill, the num-
ber of Texas facilities providing abortions declined,1 from 41
in 2012 to 17 in June 2016. Women whose nearest clinic closed
traveled farther to access abortion services than those whose
nearest clinic remained open.2 Overall, abortions declined 14%
in Texas between 2013 and 2014.3
We hypothesized that the decline in abortions would be
greater as the change in distance to the nearest open facility
increased.
Methods | This study was approved by the institutional
review board of the University of Texas at Austin. Since
2012, we have tracked the number and location of facilities
providing abortions in Texas.1 Information on the location of
abortion-providing facilities in Arkansas, Louisiana,
New Mexico, and Oklahoma was also obtained. County-level
data on abortions received by Texas residents both in and
out of state in 2012 and 2014 were obtained from the website
of the Department of State Health Services.3 The distance
from the centroid of each Texas county to the nearest open
facility providing abortions in 2012 and 2014 was calculated
using the geodist module in Stata (StataCorp), version 13.
Any facility open for at least 6 months in a year was consid-
ered open.
Counties were categorized according to whether they
had a facility providing abortions in 2014. Those that did not
were grouped into 5 categories based on change in distance
Figure. Change in Travel Distance From a Texas County to the Nearest US Facility Offering Abortion,
2012 to 2014
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to the nearest facility, ranging from 0 to 100 miles or greater.
For each category, the percentage of change in the number of
abortions occurring in 2012 and 2014 to residents of those
counties was calculated along with 95% CIs4; P value for
trend was assessed using linear regression in Stata. Two-
sided P values less than .05 were considered significant.
Counties with an open facility in 2014 were not included
because distance to the nearest facility was not a comparable
determinant of access.
Results | In 2012, 66 098 abortions were performed among Texas
residents (97 out of state). In 2014, 53 882 abortions were per-
formed among Texas residents (754 out of state). Of 254 coun-
ties, there were 41 facilities in 17 counties in 2012 and there
were 21 facilities in 6 counties in 2014.
Counties in West and South Texas had the greatest
change in distance to a facility (Figure). The mean distance
change was 51 miles (SD, 68) and the median change was 13
miles (interquartile range, 0-85). Counties that had an open
facility in 2014 (all in large metropolitan areas) had minimal
distance changes (0-5 miles) and a 15.9% (95% CI, 14.8%-
17.0%) decline in abortions (Table).
Among counties without an open facility in 2014, the
decline in abortions increased as the distance change to the
nearest facility increased (P < .001 for trend). Counties with
no facility in 2014 but no change in distance to a facility
between 2012 and 2014 had a 1.3% (95% CI, −1.5% to 4.0%)
decline in abortions. When the change in distance was 100
miles or more, the number of abortions decreased 50.3%
(95% CI, 48.0% to 52.7%).
Discussion | In Texas counties without a facility in 2014, an in-
crease in distance to the nearest facility was associated with a
decline in abortions between 2012 and 2014. However, abor-
tions also declined among women in counties with an open fa-
cility in 2014, indicating that there were other factors related
to the decrease, such as limited capacity to meet demand for
services.5 In counties with no facility and no change in dis-
tance, the decline in abortion was minimal. Many of these
counties were in East Texas where family planning services
were disrupted,6 likely leading to increased demand for abor-
tion that offset the increased capacity barriers women faced.
Limitations include that official statistics may underesti-
mate out-of-state abortions and not capture abortions among
women who self-induced or traveled to Mexico for care. Dis-
tance to the nearest facility may not reflect actual distance trav-
eled for women seeking second-trimester or medication abor-
tion, which are not available at every facility.
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Table. Change in Number of Abortions to Residents of Texas Counties by Change in Distance to Nearest US Facility Providing Abortion,
2012 to 2014
No. of Counties
No. of Abortions by Year
Decrease in No. of Abortions, % (95% CI)c2012a 2014b
County had ≥1 open facility in 2014 6 43 304 36 421 15.9 (14.8 to 17.0)
Change in distance to nearest facility between 2012 and 2014 in counties with no facility in 2014, mile
0 79 8627 8516 1.3 (−1.5 to 4.0)
1-24 55 3987 3479 12.7 (9.0 to 16.4)
25-49 25 1671 1249 25.3 (20.1 to 30.4)
50-99 33 2538 1633 35.7 (31.9 to 39.4)
≥100 56 4589 2279 50.3 (48.0 to 52.7)
Totald 254 64 716 53 577 17.2 (16.3 to 18.1)
a Column does not include 1382 abortion cases with missing information on
Texas county of residence.
b Column does not include 305 abortion cases with missing information on
Texas county of residence.
c P value for trend for percentage of decrease in number of abortions among
counties with no open facility in 2014 was less than .001. The 95% CIs were
estimated using the delta method assuming a binomial distribution,
a constant proportion of pregnancies ending in induced abortion across
groups, and no change in the number of pregnancies between
2012 and 2014.
d Indicates total No. of counties in Texas and total No. of abortions for 2012
and 2014.
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COMMENT & RESPONSE
Interventions to Lower Low-Density Lipoprotein
Cholesterol and Cardiovascular Risk
To the Editor Dr Silverman and colleagues1 examined the rela-
tionship between lowering low-density lipoprotein choles-
terol (LDL-C) and cardiovascular risk reduction among differ-
ent statin and nonstatin therapies. We think that further
discussion about the statin therapeutic group is needed.
In the study,1 the entire statin class was investigated with-
out distinguishing the different types and doses of statin
therapy administered. This approach might be overly simplis-
tic. The number of different statins is large, with variation in
the active compounds, associated effects, and therapeutic
doses. Several reports indicate that there is a gradient in the
cardiovascular risk reduction as well as the safety profile across
different types and doses of statins, with lower efficacy asso-
ciated with moderate doses as opposed to more intensive dose
therapy.2,3 The inclusion of lower doses might blunt a more ro-
bust effect of high-dose statin therapy on cardiovascular out-
come reduction.
Moreover, this type of meta-analysis does not fully take
into account the differences in the length of the individual trials
with respect to cardiovascular benefits. Some of the nonsta-
tin lipid-lowering trials4,5 reported benefits only after 7.4 years
and 9.7 years, whereas most of the statin trials showed ben-
efits at much earlier time points. These findings suggest that
the beneficial effects of statins occur more rapidly and may not
be entirely dependent on cholesterol reduction but on pleio-
tropic effects, which are different across the various types
(lipophilic vs hydrophilic) of statins administered.
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To the Editor The article by Dr Silverman and colleagues1 dis-
cussed comparatively similar benefits of all currently avail-
able LDL-C–lowering therapies, particularly those that lower
LDL-C by upregulation of LDL-C receptors or by decreasing
LDL-C production, on major cardiovascular events.
When LDL-C–lowering therapies are prescribed, whether
for primary or secondary prevention, it typically means long-
term therapy (and in most cases a lifelong commitment) to
achieve the anticipated benefits of preventing major cardio-
vascular events. Therefore, careful consideration of the
safety profile of all available therapies and their interactions
with other medications, which many patients with moderate
to high cardiovascular risk are taking for comorbidities,
becomes important, especially when their effectiveness is
comparable.
The meta-regression analysis compared the relative ben-
efits of all LDL-C–lowering therapies but did not compare their
safety profiles. Although each therapy has its own set of ad-
verse effects, making it difficult to compare them across a range
of therapies, at least the proportion of patients who experi-
enced adverse effects from each therapy could have been com-
pared. This information would have provided objective evi-
dence of the relative risk and benefit of each LDL-C–lowering
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